-$0.27 Earnings Per Share Expected for Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) This Quarter

Brokerages expect Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) to report earnings per share (EPS) of ($0.27) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Neoleukin Therapeutics’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.24). Neoleukin Therapeutics reported earnings per share of ($0.20) in the same quarter last year, which indicates a negative year-over-year growth rate of 35%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 11th.

On average, analysts expect that Neoleukin Therapeutics will report full-year earnings of ($1.09) per share for the current financial year, with EPS estimates ranging from ($1.17) to ($0.95). For the next fiscal year, analysts expect that the company will report earnings of ($1.18) per share, with EPS estimates ranging from ($1.33) to ($1.02). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Neoleukin Therapeutics.

Neoleukin Therapeutics (NASDAQ:NLTX) last released its quarterly earnings results on Thursday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04).

Several brokerages recently commented on NLTX. Zacks Investment Research cut Neoleukin Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 31st. Mizuho reissued a “buy” rating and issued a $21.00 price target on shares of Neoleukin Therapeutics in a research note on Sunday, April 11th. Finally, HC Wainwright reissued a “buy” rating on shares of Neoleukin Therapeutics in a research note on Wednesday, April 28th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $21.83.

Shares of NASDAQ:NLTX traded up $0.16 during midday trading on Thursday, hitting $10.14. 4,796 shares of the stock were exchanged, compared to its average volume of 218,631. The business’s 50-day simple moving average is $10.96. Neoleukin Therapeutics has a 12 month low of $9.38 and a 12 month high of $17.95. The firm has a market cap of $429.39 million, a PE ratio of -13.31 and a beta of 1.03.

In related news, SVP Carl Walkey sold 2,400 shares of the stock in a transaction on Wednesday, April 28th. The stock was sold at an average price of $12.58, for a total value of $30,192.00. Following the completion of the sale, the senior vice president now directly owns 1,357,162 shares of the company’s stock, valued at approximately $17,073,097.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jonathan G. Drachman purchased 40,000 shares of the stock in a transaction that occurred on Thursday, June 3rd. The stock was bought at an average cost of $9.48 per share, with a total value of $379,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,238,686 shares in the company, valued at approximately $21,222,743.28. The disclosure for this purchase can be found here. Insiders have sold 16,200 shares of company stock worth $190,476 over the last ninety days. 10.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Neoleukin Therapeutics by 0.9% in the 1st quarter. BlackRock Inc. now owns 2,709,825 shares of the company’s stock valued at $33,358,000 after buying an additional 24,915 shares during the last quarter. Point72 Asset Management L.P. raised its position in Neoleukin Therapeutics by 9.4% in the 1st quarter. Point72 Asset Management L.P. now owns 1,308,600 shares of the company’s stock valued at $16,109,000 after buying an additional 112,875 shares during the last quarter. Geode Capital Management LLC raised its position in Neoleukin Therapeutics by 13.0% in the 1st quarter. Geode Capital Management LLC now owns 537,242 shares of the company’s stock valued at $6,613,000 after buying an additional 61,936 shares during the last quarter. Morgan Stanley raised its position in Neoleukin Therapeutics by 123.8% in the 4th quarter. Morgan Stanley now owns 430,284 shares of the company’s stock valued at $6,067,000 after buying an additional 238,056 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Neoleukin Therapeutics by 1,091.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 338,530 shares of the company’s stock valued at $4,167,000 after buying an additional 310,107 shares during the last quarter. 65.51% of the stock is owned by institutional investors and hedge funds.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

See Also: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on Neoleukin Therapeutics (NLTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neoleukin Therapeutics (NASDAQ:NLTX)

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.